Orexigen Therapeutics

Orexigen Therapeutics ( OREX) is a biopharmaceutical company focused on the development of pharmaceutical product candidates for the treatment of obesity. This stock closed up 9.7% to $5.95 on Thursday.

Thursday's Range: $5.37-$6.00

52-Week Range: $3.10-$7.73

Volume: 2.19 million

Three-Month Average Volume: 1.31 million

From a technical perspective, OREX trended higher here back above its 50-day moving average of $5.70 with above-average volume. This move is quickly pushing shares of OREX within range of triggering a near-term breakout trade. That trade will hit if OREX manages to clear some near-term overhead resistance levels at $6.11 to $6.25 with high volume.

Traders should now look for long-biased trades in OREX as long as it's trending above its 50-day at $5.70 and then once it sustains a move or close above those breakout levels with volume that hits near or above 1.31 million shares. If that breakout hits soon, then OREX will set up to re-test or possibly take out its next major overhead resistance levels at $6.68 to $7.73. Any high-volume move above $7.73 would then push OREX into new 52-week-high territory, which is bullish technical price action.

MGIC Investment

MGIC Investment ( MTG) is a provider of private mortgage insurance in the U.S. This stock closed up 6.4% to $2.98 on Thursday.

Thurday's Range: $2.36-$3.15

52-Week Range: $0.66-$5.15

Volume: 35.76 million

Three-Month Average Volume: 4.90 million

Shares of MTG soared on Thursday after revenue topped analysts' estimates and delinquencies declined over the course of the year. The company's CEO also said the firm may raise capital to cut a risk measure that breached regulatory limits.

From a technical perspective, MTG soared higher here back above its 50-day moving average of $2.76 with monster upside volume. This stock has been trading in consolidation pattern for the last two months, with shares moving between $2.36 on the downside and $3.33 on the upside. The spike on Thursday is now quickly pushing shares of MTG within range of breaking out above the upper-end of its recent range. That breakout will hit if MTG manages to clear some near-term overhead resistance levels at $2.96 to $3.33 with high volume.

If you liked this article you might like

Goodbye CytRx, Your Game Is Over

For These Small-Cap Biotech CEOs, Stock Promotion, Not Drug Development, Was Priority No. 1

The 'Gnarly 9' Biotechs Will Test the FDA's Mettle

Could These 9 Drugs Gain FDA Approval in the Age of Trump?

The 'Gnarly 9' Biotechs Will Test the FDA's Mettle